Delafloxacin meglumine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H524947

CAS#: 352458-37-8 (meglumine)

Description: Delafloxacin is a fluoroquinolone antibiotic agent. Delafloxacin meglumine is more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. In vitro: Delafloxacin meglumine exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs


Chemical Structure

img
Delafloxacin meglumine
CAS# 352458-37-8 (meglumine)

Theoretical Analysis

Hodoodo Cat#: H524947
Name: Delafloxacin meglumine
CAS#: 352458-37-8 (meglumine)
Chemical Formula: C25H29ClF3N5O9
Exact Mass: 0.00
Molecular Weight: 635.980
Elemental Analysis: C, 47.21; H, 4.60; Cl, 5.57; F, 8.96; N, 11.01; O, 22.64

Price and Availability

Size Price Availability Quantity
100mg USD 350 2 Weeks
250mg USD 700 2 Weeks
500mg USD 1050 2 Weeks
Bulk inquiry

Related CAS #: 189279-58-1 (free acid)   352458-37-8 (meglumine)  

Synonym: Delafloxacin meglumine; ABT-492; ABT 492; ABT492; RX-3341; RX 3341; RX3341; WQ-3034; WQ 3034; WQ3034; Baxdela.

IUPAC/Chemical Name: (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1:1)

InChi Key: AHJGUEMIZPMAMR-WZTVWXICSA-N

InChi Code: InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

SMILES Code: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(C1=CN(C2=NC(N)=C(F)C=C2F)C3=C(C=C(F)C(N4CC(O)C4)=C3Cl)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) is a broad-spectrum fluoroquinolone antibiotic that has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia.
In vitro activity: Delafloxacin exhibited excellent in vitro activity against 117 N. gonorrhoeae strains (110 clinical N. gonorrhoeae isolates and 7 GISP reference strains). In general, MICs of delafloxacin (≤0.001 to 0.25 μg/ml) were lower than those of 5 comparator antimicrobials but comparable to those of ceftriaxone (≤0.001 to 0.25 μg/ml) and cefixime (≤0.001 to 0.5 μg/ml) (Table 1). The highest delafloxacin MIC observed was 0.25 μg/ml in a single clinical isolate. Although resistant mutants arose at a frequency between 1.7 × 10−7 and 8.9 × 10−8 at 2× the original delafloxacin MICs for the other two ciprofloxacin-resistant N. gonorrhoeae strains (13199 and 131011), the mutation frequencies were below the limit of detection at 4×, 8×, and 16× the MIC (
In vivo activity: The objectives of our experiments were to characterize the in vivo efficacy of delafloxacin using a neutropenic murine lung infection model for three common respiratory tract pathogen groups, including S. aureus, S. pneumoniae, and K. pneumoniae. At the doses studied, exposure to delafloxacin increased in a dose-dependent manner across the dose range. Cmax concentrations ranged from 2 to 71 mg/liter. AUC0–∞ values ranged from 2.8 to 152 mg h/liter and were linear across the 2.5- to 160-mg dosing range (R2 of 0.99). Delafloxacin was highly effective against S. aureus (Fig. 2A). Against all four strains we observed a decrease of 1.5 to 2.2 log10 CFU in organism burden from untreated controls at even the lowest dose studied, and for two strains (MW2 and R2527) there was net bactericidal activity at the lowest dose. At the maximal doses studied, there was a >4-log10 kill from initial burden for all S. aureus strains. Likewise, delafloxacin was very potent against S. pneumoniae (Fig. 2B). The data presented will be useful for delafloxacin dosing regimen optimization for the treatment of respiratory tract infections and for setting the preliminary breakpoints. Reference: Antimicrob Agents Chemother. 2016 Aug; 60(8): 4764–4769. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958193/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 39.0 61.32
H2O 75.0 117.93

Preparing Stock Solutions

The following data is based on the product molecular weight 635.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. PMID: 27458220; PMCID: PMC5038254. 2. Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3106-11. doi: 10.1128/AAC.02798-15. PMID: 26976873; PMCID: PMC4862482. 3. Lepak AJ, Andes DR. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764- 9. doi: 10.1128/AAC.00647-16. PMID: 27216072; PMCID: PMC4958193.
In vitro protocol: 1. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. PMID: 27458220; PMCID: PMC5038254. 2. Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3106-11. doi: 10.1128/AAC.02798-15. PMID: 26976873; PMCID: PMC4862482.
In vivo protocol: 1. Lepak AJ, Andes DR. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764- 9. doi: 10.1128/AAC.00647-16. PMID: 27216072; PMCID: PMC4958193.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548907/ PubMed PMID: 31644214.

2: Koeth LK, DiFranco-Fisher JM, Hardy DJ, Mortensen JE, Palavecino E, Windau AW. Multilab evaluation of delafloxacin MIC Test Strip against Gram-negative and Gram-positive organisms. Diagn Microbiol Infect Dis. 2019 Nov;95(3):114868. doi: 10.1016/j.diagmicrobio.2019.07.006. Epub 2019 Jul 30. PubMed PMID: 31447245.

3: Iregui A, Khan Z, Malik S, Landman D, Quale J. Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY. Clin Infect Dis. 2019 Aug 15. pii: ciz787. doi: 10.1093/cid/ciz787. [Epub ahead of print] PubMed PMID: 31412357.

4: Zhao M, Lepak AJ, Marchillo K, Andes DR. In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01131-19. doi: 10.1128/AAC.01131-19. Print 2019 Oct. PubMed PMID: 31332063; PubMed Central PMCID: PMC6761510.

5: Lan SH, Lai CC, Lu LC, Chang SP, Huang HT. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019 May 27;12:1415-1423. doi: 10.2147/IDR.S202160. eCollection 2019. PubMed PMID: 31213859; PubMed Central PMCID: PMC6549389.

6: Hook EW 3rd, Golden MR, Taylor SN, Henry E, Tseng C, Workowski KA, Swerdlow J, Nenninger A, Cammarata S. Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study. Sex Transm Dis. 2019 May;46(5):279-286. doi: 10.1097/OLQ.0000000000000971. PubMed PMID: 30985632.

7: Bassetti M, Hooper D, Tillotson G. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S233-S240. doi: 10.1093/cid/ciy1080. PubMed PMID: 30957169; PubMed Central PMCID: PMC6451993.

8: Giordano PA, Pogue JM, Cammarata S. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S223-S232. doi: 10.1093/cid/ciz006. PubMed PMID: 30957167; PubMed Central PMCID: PMC6452004.

9: Tulkens PM, Van Bambeke F, Zinner SH. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S213-S222. doi: 10.1093/cid/ciy1079. PubMed PMID: 30957164; PubMed Central PMCID: PMC6452001.

10: Corey GR, McKinnell JA, Rybak MJ. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S191-S192. doi: 10.1093/cid/ciy1089. PubMed PMID: 30957163; PubMed Central PMCID: PMC6451998.

11: Hook EW 3rd, Golden MR, Taylor SN, Henry E, Tseng C, Swerdlow J, Nenninger A, Cammarata S. Efficacy and safety of single dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, non-inferiority, Phase 3, multicenter, randomized study. Sex Transm Dis. 2019 Jan 19. doi: 10.1097/OLQ.0000000000000971. [Epub ahead of print] PubMed PMID: 30676487.

12: Kaul G, Kapoor E, Dasgupta A, Chopra S. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Drugs Today (Barc). 2018 Nov;54(11):657-666. doi: 10.1358/dot.2018.54.11.2878151. Review. PubMed PMID: 30539165.

13: Adler A, Chaudhry S, Goldberg T. Baxdela(TM) (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections. P T. 2018 Nov;43(11):662-666. PubMed PMID: 30410281; PubMed Central PMCID: PMC6205123.

14: Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infect Dis. 2018 Sep 10;5(10):ofy220. doi: 10.1093/ofid/ofy220. eCollection 2018 Oct. PubMed PMID: 30349845; PubMed Central PMCID: PMC6189306.

15: Shiu J, Ting G, Kiang TK. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin. Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):305-317. doi: 10.1007/s13318-018-0520-8. Review. PubMed PMID: 30324277.

16: Markham A. Correction to: Delafloxacin: First Global Approval. Drugs. 2018 Oct;78(15):1651. doi: 10.1007/s40265-018-0990-7. PubMed PMID: 30284698; PubMed Central PMCID: PMC6208763.

17: Eudaley S. Delafloxacin (Baxdela) for Skin Infections. Am Fam Physician. 2018 Aug 15;98(4):246-247. PubMed PMID: 30215969.

18: Saravolatz LD, Stein GE. Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. Clin Infect Dis. 2019 Mar 5;68(6):1058-1062. doi: 10.1093/cid/ciy600. PubMed PMID: 30060092.

19: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500923/ PubMed PMID: 29999982.

20: Ocheretyaner ER, Park TE. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Rev Anti Infect Ther. 2018 Jul;16(7):523-530. doi: 10.1080/14787210.2018.1489721. Epub 2018 Jun 26. Review. PubMed PMID: 29911455.